Medication Safety

Semaglutide Side Effects: Ozempic, Wegovy, and Rybelsus

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus. Across these products the most common side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation, usually mild to moderate and easing with slow dose escalation. Serious risks per the FDA labels include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors. Discuss any persistent or severe symptoms with your prescriber.

Side Effects at a Glance

Common / Manageable

NauseaThe most common reaction across semaglutide products; usually worst after a dose increase.
VomitingReported across the product line, more likely at higher doses.
DiarrheaCommon, especially early in treatment.
Abdominal painUsually mild; persistent or severe pain should be reported.
ConstipationCommon; related to slowed gastric emptying.
Decreased appetiteExpected given the mechanism; can reduce food and fluid intake.

Serious / Rare

Thyroid C-cell tumors (boxed warning)Semaglutide caused thyroid C-cell tumors in rodents. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Human risk is undetermined.
PancreatitisAcute pancreatitis has been reported across semaglutide products; severe persistent abdominal pain warrants prompt evaluation.
Gallbladder diseaseCholelithiasis and acute gallbladder disease have occurred, particularly with rapid weight loss.
Acute kidney injuryDehydration from GI side effects can worsen kidney function.
HypoglycemiaRisk increases with insulin or a sulfonylurea in people with type 2 diabetes.
Diabetic retinopathy complicationsObserved more often with semaglutide in SUSTAIN-6 among people with a history of diabetic retinopathy.
Hypersensitivity reactionsSerious allergic reactions including anaphylaxis and angioedema have been reported.

Semaglutide vs its brand names

Semaglutide is the molecule; Ozempic and Rybelsus are FDA-approved for type 2 diabetes (Rybelsus is the oral tablet) and Wegovy is approved at a higher dose for chronic weight management. The side-effect profile is broadly similar because the active ingredient is the same, though frequencies differ by dose and formulation. Always check the specific product’s prescribing information, and rely on your prescriber for guidance on your formulation.

Managing common side effects

Label-consistent strategies many people and clinicians use to ease GI symptoms are below. They are educational and do not replace medical advice; severe or persistent symptoms should be reported to your prescriber.

Eat smaller, more frequent meals and stop when full.
Limit fried and very high-fat foods, which worsen nausea for many.
Stay hydrated, particularly with vomiting or diarrhea, to protect the kidneys.
Follow your prescriber’s titration schedule rather than escalating quickly.
Report severe abdominal pain, vision changes, or signs of dehydration promptly.

A note on compounded semaglutide

Compounded semaglutide is not FDA-approved and is not manufactured under the same controls as Ozempic, Wegovy, or Rybelsus. Potency and purity can vary between compounders, which can affect both effectiveness and the side-effect experience. If you are considering or using a compounded product, discuss it directly with your prescriber and verify the pharmacy.

The Centurion companion approach

Centurion Coach is built to support a prescribed semaglutide regimen, not to replace it or your clinician. The companion role is to help you track symptoms against your dose so patterns are visible to you and your prescriber, and to protect lean muscle. Because weight loss on a GLP-1 can include muscle as well as fat, Centurion emphasizes adequate protein and resistance training to help preserve muscle while losing weight. This is general nutrition and training education — it does not treat side effects, and medical decisions stay with your prescriber.

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.

FAQ

Frequently Asked Questions

Across Ozempic, Wegovy, and Rybelsus, the FDA labels list gastrointestinal reactions as most common: nausea, vomiting, diarrhea, abdominal pain, and constipation. Decreased appetite is expected given how the medication works.

Both contain semaglutide, so the side-effect profile is broadly similar. Frequencies can differ because Wegovy is dosed higher (2.4 mg) for weight management while Ozempic is dosed for type 2 diabetes. Check the specific product label and ask your prescriber.

The labels carry a boxed warning for thyroid C-cell tumors and list pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia (with insulin or a sulfonylurea), diabetic retinopathy complications, and serious allergic reactions. Seek care for severe abdominal pain, allergic symptoms, or vision changes.

Compounded semaglutide is not FDA-approved and is not made under the same manufacturing controls, so potency and purity can vary. That variability can affect both results and side effects. Discuss any compounded product with your prescriber and verify the pharmacy.

Common, label-consistent steps include smaller meals, limiting high-fat foods, staying hydrated, and following the prescribed slow titration. These do not replace medical advice; report severe or persistent symptoms to your prescriber.

Sources

Ozempic (semaglutide) injection — Prescribing Information — FDA / DailyMed
Wegovy (semaglutide) injection — Prescribing Information — FDA / DailyMed
Rybelsus (semaglutide) tablets — Prescribing Information — FDA / DailyMed
AGA Clinical Guidance: management of patients taking GLP-1 receptor agonists — American Gastroenterological Association

Reviewed for accuracy by the Centurion Metrics Clinical Team. Last reviewed June 15, 2026. Content is sourced from FDA prescribing information and major clinical bodies.